Differences in the Acute Pulmonary Vascular Effects of Oxygen with Nitric Oxide and Diltiazem: Implications for the Long-term Treatment of Pulmonary Arterial Hypertension

被引:4
作者
Day, Ronald W. [1 ,2 ]
机构
[1] Univ Utah, Salt Lake City, UT USA
[2] Primary Childrens Med Ctr, Salt Lake City, UT 84113 USA
关键词
Calcium Channel Blocker; Nitric Oxide; Oxygen; Pulmonary Arterial Hypertension; CALCIUM-CHANNEL BLOCKERS; CHILDREN; ADULTS; AGENT;
D O I
10.1111/j.1747-0803.2012.00704.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Right heart catheterization is performed in patients with pulmonary arterial hypertension to determine the severity of disease and their pulmonary vascular reactivity. This study sought to determine whether the acute pulmonary vasodilatory effects of diltiazem and oxygen with nitric oxide are similar enough to support the practice of using nitric oxide as a surrogate agent to identify patients to treat with an oral calcium channel blocker alone. Design. Retrospective descriptive study. Setting. A tertiary medical center for children. Patients. Twenty-four individuals (7 months to 17 years of age) with pulmonary arterial hypertension who met criteria for a favorable acute pulmonary vasodilatory response to oxygen with nitric oxide, and were also evaluated with intravenous diltiazem. Interventions. Right heart catheterization and an evaluation of pulmonary vascular reactivity. Outcome Measures. The pulmonary vasodilatory effects of oxygen, oxygen with nitric oxide, and intravenous diltiazem; and the need for medications other than amlodipine to decrease long-term pulmonary arterial pressure. Results. Oxygen, oxygen with nitric oxide, and diltiazem acutely decreased pulmonary arterial pressure. Diltiazem also decreased systemic arterial pressure. A lower mean pulmonary arterial pressure was achieved with oxygen and nitric oxide than with diltiazem (30 +/- 2mm Hg vs. 39 +/- 3mm Hg, P<.05). Half of the patients who were treated long term with amlodipine alone failed to develop a long-term 20% decrease in pulmonary arterial pressure and were treated with additional medications. Conclusions. The combination of oxygen and nitric oxide decreased pulmonary arterial pressure more than a dose of intravenous diltiazem that was large enough to decrease systemic arterial pressure. Oxygen and nitric oxide may identify patients who can be treated safely with a calcium channel blocker; however, they should not be used as surrogates to identify patients to treat with a calcium channel blocker alone.
引用
收藏
页码:71 / 77
页数:7
相关论文
共 13 条
[1]   Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing [J].
Atz, AM ;
Adatia, I ;
Lock, JE ;
Wessel, DL .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (03) :813-819
[2]   Medical therapy for pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines [J].
Badesch, DB ;
Abman, SH ;
Ahearn, GS ;
Barst, RJ ;
McCrory, DC ;
Simonneau, G ;
McLaughlin, VV .
CHEST, 2004, 126 (01) :35S-62S
[3]  
Balzar DT, 2002, CIRCULATION S1, V106, pI
[4]   Pulmonary arterial hypertension: a comparison between children and adults [J].
Barst, R. J. ;
Ertel, S. I. ;
Beghetti, M. ;
Ivy, D. D. .
EUROPEAN RESPIRATORY JOURNAL, 2011, 37 (03) :665-677
[5]   PHARMACOLOGICALLY INDUCED PULMONARY VASODILATATION IN CHILDREN AND YOUNG-ADULTS WITH PRIMARY PULMONARY-HYPERTENSION [J].
BARST, RJ .
CHEST, 1986, 89 (04) :497-503
[6]   Vasodilator Testing with Nitric Oxide and/or Oxygen in Pediatric Pulmonary Hypertension [J].
Barst, Robyn J. ;
Agnoletti, Gabriella ;
Fraisse, Alain ;
Baldassarre, James ;
Wessel, David L. .
PEDIATRIC CARDIOLOGY, 2010, 31 (05) :598-606
[7]   PULMONARY VASODILATORY EFFECTS OF 12 AND 60 PARTS-PER-MILLION INHALED NITRIC-OXIDE IN CHILDREN WITH VENTRICULAR SEPTAL-DEFECT [J].
DAY, RW ;
LYNCH, JM ;
SHADDY, RE ;
ORSMOND, GS .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (02) :196-198
[8]   Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria [J].
Douwes, Johannes M. ;
van Loon, Rosa L. E. ;
Hoendermis, Elke S. ;
Vonk-Noordegraaf, Anton ;
Roofthooft, Marcus T. R. ;
Talsma, Melle D. ;
Hillege, Hans L. ;
Berger, Rolf M. F. .
EUROPEAN HEART JOURNAL, 2011, 32 (24) :3137-3146
[9]   ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association [J].
McLaughlin, Vallerie V. ;
Archer, Stephen L. ;
Badesch, David B. ;
Barst, Robyn J. ;
Farber, Harrison W. ;
Lindner, Jonathan R. ;
Mathier, Michael A. ;
McGoon, Michael D. ;
Park, Myung H. ;
Rosenson, Robert S. ;
Rubin, Lewis J. ;
Tapson, Victor F. ;
Varga, John ;
Harrington, Robert A. ;
Anderson, Jeffrey L. ;
Bates, Eric R. ;
Bridges, Charles R. ;
Eisenberg, Mark J. ;
Ferrari, Victor A. ;
Grines, Cindy L. ;
Hlatky, Mark A. ;
Jacobs, Alice K. ;
Kaul, Sanjay ;
Lichtenberg, Robert C. ;
Lindner, Jonathan R. ;
Moliterno, David J. ;
Mukherjee, Debabrata ;
Pohost, Gerald M. ;
Rosenson, Robert S. ;
Schofield, Richard S. ;
Shubrooks, Samuel J., Jr. ;
Stein, James H. ;
Tracy, Cynthia M. ;
Weitz, Howard H. ;
Wesley, Deborah J. .
CIRCULATION, 2009, 119 (16) :2250-2294
[10]   Inhaled nitric oxide in primary pulmonary hypertension - A safe and effective agent for predicting response to nifedipine [J].
Ricciardi, MJ ;
Knight, BP ;
Martinez, FJ ;
Rubenfire, M .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (04) :1068-1073